Vijendra Nalamothu

Biography

  NALAMOTHU earned his doctoral degree in Pharmaceutics from University of the Sciences’ Philadelphia College of Pharmacy working under Dr. Joseph Schwartz and Dr. Rod Wigent. Prior to Tergus, he was employed with Promius Pharma, a wholly owned subsidiary of Dr. Reddy’s Laboratories, Inc., as the Global Head of Dermatology R&D. He spearheaded the development of specialty branded dermatological products from concept to commercialization including various human clinical trials in US, Europe and India. In addition to North American branded products for Promius, he also developed branded dermatology products for various other countries wherein Dr. Reddy’s markets products for various skin disorders. His interests include novel dosage form design and development of topical drug products, developing new disease models in animals, designing proof of concept studies in humans, animal toxicology studies, human clinical trials, process scale-up and manufacturing. Prior to joining Promius, he served as the Head of Early Compound Assessment group for Sanofi-aventis’ Worldwide Dermatology (Dermik). During his tenure at Dermik’s formulation and early compound assessment groups, Vijendra’s efforts focused on both known molecules and new chemical entities.   Vijendra is able to draw from an exceptional educational background that combined scientific study with pragmatic, hands-on experience solving R&D challenges. He has co/authored numerous publications and has patents for few of his inventions. He has presented his research findings in various international meetings. He is an invited speaker at various meetings and serves as a member of Society for Investigative Dermatology, American Association of Pharmaceutical Sciences and Controlled Release Society. Dr. Nalamothu also serves on the board of few Pharmaceutical and Technology companies and is a member of several pharmaceutical research focus and discussion groups.  

Research Interest

Investigative Dermatology